Your browser doesn't support javascript.
loading
Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Wang, Q; Wang, Q; Wang, S F; Jiao, L J; Zhang, R X; Zhong, Y; Zhang, J; Xu, L.
Affiliation
  • Wang Q; Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine.
  • Wang Q; Department of Oncology, Shanghai Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine.
  • Wang SF; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and.
  • Jiao LJ; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.; and.
  • Zhang RX; Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine.
  • Zhong Y; Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, U.S.A.
  • Zhang J; Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, U.S.A.
  • Xu L; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.; and.
Curr Oncol ; 24(4): e269-e276, 2017 Aug.
Article in En | MEDLINE | ID: mdl-28874897
ABSTRACT

BACKGROUND:

The concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma.

METHODS:

We searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0 StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis).

RESULTS:

Sixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr 0.49; 95% ci 0.35 to 0.68; p < 0.001), pfs (hr 0.66; 95% ci 0.51 to 0.84; p = 0.001), and 2-year survival rate (rr 0.63; 95% ci 0.44 to 0.92, p = 0.017), and a significant improvement in performance status (rr 0.68; 95% ci 0.61 to 0.75; p < 0.001).

CONCLUSIONS:

For patients who show non-progression-including stable disease, partial response, or complete response-after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Language: En Journal: Curr Oncol Year: 2017 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Language: En Journal: Curr Oncol Year: 2017 Type: Article